This new method for determining pancreatic isoamylase (EC 3.2.1.1) in serum involves two monoclonal antibodies: one immobilized in a microtitration well (the capture antibody), the other biotinylated. After the sample is incubated with the two antibodies, the captured immunocomplex is quantified by adding streptavidin labeled with a europium chelator and measuring the specific Eu3 fluorescence in a time-resolved mode. Three assay protocols are proposed, involving incubation times of 90, 45, or 25 mm. The assay has low (0.005%) cross-reactivity with the salivary isoenzyme. Analytical performance was satisfactory. Results correlate well with results obtained by measuring total amylase activity or by measuring pancreatic isoamylase activity after immunoinhibition. Unlike numerous current amylase assays, this method measures enzyme mass rather than enzyme activity. Potentially, this is a highly specific assay.
are radioimmunoassay (15, 16), immunoinhibition (17-20), and iminunoextraction (21, 22) .
Here we report our evaluation of the use of three commercially available monoclonal antibodies to develop a "two-site, sandwich-type" noncompetitive immunoassay of pancreatic isoamylase in serum. We selected a suitable antibody pair, then immobilized one of the pair onto white microtitration wells to be used as "capture" antibody; the other antibody was biotinylated and used for detection. We used labeled streptavidin to quantify the final immunocomplex, as detailed elsewhere (23-25). To our knowledge, this is the first report of a specific immunological assay of pancreatic amylase based on using two monoclonal antibodies in a noncompetitive immunoassay design.
Materials and Methods

Instrumentation
For solid-phase time-resolved fluorometric measurements we used the Model 615 Immunoanalyzer (CyberFluor Inc., Toronto, Ontario), which performs data reduction. We used a single-beam Model 240 spectrophotometer (Gilford Instruments, Oberlin, OH) to perform manual assays for total and pancreatic amylase and lipase, as recommended by the kit manufacturer (see below).
Materials
The europium chelator 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) was synthesized as described elsewhere (26). Streptavidin and bovine serum albumin were from Sigma Chemical Co., St. Louis, MO 63178. EuCl3 hexahydrate was from Aldrich Chemical Co., Milwaukee, WI -53201. Sulfosuccinimidyl-6-(biotinamido)-hexanoate was from Pierce Chemical Co., Rockford, IL 61105. All other chemicals were from Sigma. White, opaque, 12-well microtiter strips (Immulon II) were products of Dynatech Labs, Alexandria, VA 22314.
The coating buffer was 50 mmoIJL Tris solution, pH 7.80. The blocking buffer was 50 mmol/L sodium phosphate solution, pH 7.4, containing 9 g of NaCl and 10 g of albumin per liter. The assay buffer was 50 mmol/L Tris hydrochloride solution, pH 7.8, containing 10 g of albumin, 1 g of bovine globulins, 9 g of NaCl, and 0.5 g of sodium azide per liter. The streptavidin-europium dilution buffer consisted of 50 mmol/L Tris hydrochloride solution, pH 7.8, containing 9 g of NaC1, 40 g of albumin, 0.5 g of sodium azide, and 40 mol of Eu3 per liter. The wash solution was 9 g/L NaCl solution containing 0.5 mL of Tween 20 surfactant per liter.
Pancreatic amylase standards. Highly purified pancreatic human amylase was purchased from either Calbiochem-Behring Diagnostics, La Jolla, CA 92037, or from Aalto Scientific, Escondido, CA 92025 ("Immunopure" grade). These two preparations performed identically. We routinely used the latter, which was less expensive. The highly purified salivary amylase used for cross-reactivity studies was also obtained from Aalto Scientific. We pre-pared pancreatic amylase standards by dissolving the pure substance in 50 mmolJL Tris buffer, pH 7.80, containing 60 g of albumin per liter. Salivary amylase was dissolved in the same matrix. The concentrations of pancreatic amylase standards routinely used were 0, 20, 100, 200, 500, and 1000 tgfL.
Monoclonal
antibodies. We purchased-from Medix Biochemica AB, Kauniainen, Finland-three newly developed monoclonal antibodies for pancreatic amylase purified by ion-exchange chromatography (Code 6103) or Protein A affinity chromatography (Codes 6104 and 6105). The affinity constants (L/mol) were: 4 x io (for 6103), 1 x io (for 6104), and 1 x 1010 (for 6105). The stated (by the supplier) cross-reactivities with salivary amylase in an RIA assay were <0.1% (for 6103 and 6104) and -5% (for 6105).
Specimens. We obtained human sera from individuals being investigated for gastrointestinal abnormalities, including acute pancreatitis, and we stored these sera at 4#{176}C for no longer than four weeks until assay. Sixty-two samples were obtained from a mixed population of apparently healthy subjects, ages 20-48 years, for estimation of the normal reference interval.
Procedures
Biotinylation
of pancreatic amylase antibodies. The antibody solution (1 mL, containing 1 mg of antibody) was dialyzed twice in 5 L of isotonic (9 g/L) saline at 4#{176}C. We then diluted the dialysand with an equal volume of 0.5 mollL carbonate buffer, pH 9.1. To this solution we added 2 mg of sulfosuccinimidyl-6-(biotinamido)-hexanoate dissolved in 50 ILL of dimethyl sulfoxide and incubated the mixture for 2 h at room temperature. The solution was then dialyzed twice in 5 L of isotonic NaC1 solution at 4#{176}C. For the assay, we diluted the stock antibody solution 1000-fold in the assay buffer (working antibody solution). The stock antibody solution is stable for at least six months, and the working antibody solution is stable for at least two weeks at 4 #{176}C.
Preparation
of the streptavidin-thyroglobulin-BCPDAEuS* tracer. The preparation of BCPDA-labeled streptavidin-protein conjugates is detailed elsewhere (25). The concentration of streptavidin in the working solution of BCPDA-labeled streptavidin-thyroglobulin conjugate was 0.30 mgIL; that of EuCl3 was 40 mol/L.
Coating microtiter wells. We prepared the coating antibody solution by diluting the monoclonal pancreatic amylase antibody in the coating buffer to give a concentration of 5 mgIL. We then added 100 ILL of the antibody solution per well into wells of microtiter strips and allowed the antibody to adsorb at 4 #{176}C. After they had incubated overnight, we washed the wells twice with the wash solution, added 200 /LL of the blocking buffer per well, and incubated for 1 h at room temperature. Just before use, the wells were washed twice with the wash solution.
Comparison Methods
We used two methods for total amylase determination in 
Results
Assay Optimization
We used the three available antibodies either as "capture" (immobilized on microtiter wells) or "detection" (biotinylated) antibodies. We determined early in these studies that none of the pairs 6103-6103, 6104-6104, or 6105-6105 produced any dose-response curves, indicating that the pancreatic amylase molecule does not possess more than one copy of the antigenic determinant recognized by these antibodies. We also verified, by using either 6103 as coating and 6104 as detection, or vice versa, that these two antibodies bind to the same antigenic determinant or to antigenic determinants positioned in such a way that the binding of the one antibody prevents binding of the other. A 6103-6104 pair could not produce a dose-response curve.
The antibody combinations that produced dose-response curves were (coating antibody first) 6103-6105,6104-6105, 6105-6103, and 6104-6105. From all these systems, we selected the combination 6104 (coating)-6 105 (detection), because it gave the steepest dose-response curve.
We have studied the time course of both the first and second incubation steps. Using a constant 30-mm incubation of the secondstep, we constructed calibration curves by varying the antibody binding step from 10 to 120 min. 
Other Analytical Variables
Precision. Within-run precision (Table 1) was evaluated by assaying human control sera (supplemented serum samples) at three concentrations, 24 times each. We also assessed day-to-day precision at the same analyte concentrations for a month (12 runs). The CVs were between 9% and 13%.
Dilution test. We evaluated the dilution linearity of the procedure by assaying samples serially diluted with the zero standard ( Table 2 ). The expected values were derived from the initial concentrations of amylase in the undiluted samples. The results show reasonable agreement between expected and observed values in all cases.
Analytical recovery. Amylase-supplemented serum samples were prepared by adding known concentrations of exogenous pancreatic amylase to aliquots of pooled serum samples. Analytical recovery was assessed by analyzing the samples before and after the additions and subtracting the estimated endogenous pancreatic amylase concentrations. As shown in Table 3 , recovery ranged from 78% to 97%, averaging 86%.
Specificity. The proposed procedure was tested for crossreactivity by salivary amylase. At salivary amylase concentrations <25 000 g/L, the equivalent pancreatic amylase response was <1 g/L. Cross-reactivity, calculated at salivary amylase concentrations between 100 000 and 1 000000 g/L, was 0.005%.
High-dose hook" effect. We constructed dose-response curves with all three procedures we developed, using doses of pancreatic amylase as high as 100 000 yg/L. We found that the fluorescence signal continues to increase with increasing dose up to about 10000 g/L, then reaches a plateau, which is maintained at doses between 10000 and 100 000 g/L. Thus, the assays are free from the high-dose hook effect, at least up to 100 000 pg of pancreatic amylase per liter.
Reference Interval
Using the proposed protocol A, we analyzed samples obtained from a mixed population of 62 apparently healthy individuals ranging in age from 20 to 48 years. Figure 3 shows the frequency distribution obtained. The minimum and maximum concentrations observed were 23 and 229 gfL, respectively. The mean was 126 (SD 44) g/L; the median, 124 gfL. The range (i.e., the mean ± 2 SD) was 38-214 g/L, which is proposed as the reference interval for this assay. 
Correlation with Other Methods
We compared results obtained with the present method (protocol A) with those by two established total amylase procedures, a pancreatic amylase procedure (immunoinhibition) and a lipase procedure (Table 4) . As previously observed by others, the lipase procedure produced, in our hands, results with "negative" activity (six of 44 specimens). These specimens have been considered arbitrarily as having zero lipase activity during the correlations. We measured amylase and lipase activity and pancreatic amylase activity and mass in sequential specimens from two patients who showed marked changes in amylase values. Figure 4 summarizes the results. The patterns for all analytes used are similar in both of these cases.
Discussion
Although total amylase testing has been in use for decades for investigating pancreatic disorders, there is still interest in improving the methodology with more elaborate procedures. There is agreement in the literature that the quantification of pancreatic isoenzyme instead of total amylase activity should be preferred. However, practical isoenzyme methodologies have only recently become available. Specific monoclonal antibodies against the salivary or pancreatic isoenzymes have recently been produced. Some of these antibodies can cause inhibition in enzymatic activity, others do not. Thus, several immunoassay designs have been published that are based on either immunoinhibition or immunoextraction.
Instead of measuring enzyme or isoenzyme activity, it is also possible to measure enzyme mass by a methodology similar to a classical competitive or noncompetitive (e.g., immunoradiometric) technique. Assays of the mass of enzymes such as trypsin (27,28), creatine kinase MB isoenzyme (29) , elastase (30), amylase (15, 21) , and phospholipase-A2 (31) have recently been proposed. In some instances it has been shown that enzyme activity correlates well with immunoreactivity (29), but it must be kept in mind that immunoreactivity can be detected without enzyme activity if proenzyme forms or enzyme fragments are present in the sample. In the case of amylase, the preferred index in terms of clinical information has yet to be established.
The present assay is based on the principles of noncompetitive immunoassays, and the detection system we used has been thoroughly described before (23). To our knowledge, this is the first "two-site" immunoassay with monoclonal antibodies for pancreatic amylase. We have developed three different protocols having total incubation times of either 90, 45, or 25 mm. Thus, with the 25-mm assay, results can be generated rapidly while maintaining an acceptable turnaround time. The analytical characteristics Reports suggest that measurement of lipase instead of amylase in serum should be preferred, because lipase is more pancreato-specific. In our experience, the lipase assay is not satisfactory, because it gives negative activities in a high proportion of sera from normal individuals. Results by our assay were shown to correlate strongly with assays that measure pancreatic and total amylase activity in serum. However, our clinical evaluation should only be considered preliminary.
We are now in the process of further studying the clinical information that this assay offers in comparison to immunoinhibition isoenzyme assays. Results of these studies, which will include patients with macroamylasemia and urinary testing, will soon be reported.
